Kevin DeGeeter
Stock Analyst at Ladenburg Thalmann
(2.80)
# 1,929
Out of 4,996 analysts
45
Total ratings
34.29%
Success rate
52.58%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORIC ORIC Pharmaceuticals | Initiates: Buy | $15 | $11.12 | +34.89% | 2 | Jul 8, 2025 | |
| CRDF Cardiff Oncology | Initiates: Buy | $19 | $2.06 | +822.33% | 1 | Jul 8, 2025 | |
| NVCR NovoCure | Initiates: Buy | $30 | $12.89 | +132.74% | 4 | Jul 8, 2025 | |
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.25 | +1,660.00% | 1 | Apr 19, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $6.04 | +297.35% | 4 | Feb 25, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $22.59 | +453.34% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $4.63 | +288.77% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $3.09 | +514.89% | 1 | Nov 19, 2021 | |
| SPRO Spero Therapeutics | Downgrades: Perform | n/a | $1.89 | - | 1 | Oct 1, 2021 | |
| PANW Palo Alto Networks | Maintains: Outperform | $75 → $79 | $202.37 | -60.88% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $53.57 | +189.34% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $8.80 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $9.34 | +167.67% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $4.04 | +44,454.46% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $30.23 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.25 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.26 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,500 | $5.52 | +27,073.91% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.66 | +54,116.87% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $8.55 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $165 | $12.43 | +1,227.43% | 1 | Jun 6, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $225 | $90.50 | +148.63% | 1 | Apr 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $7.70 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.46 | - | 2 | Jan 4, 2017 |
ORIC Pharmaceuticals
Jul 8, 2025
Initiates: Buy
Price Target: $15
Current: $11.12
Upside: +34.89%
Cardiff Oncology
Jul 8, 2025
Initiates: Buy
Price Target: $19
Current: $2.06
Upside: +822.33%
NovoCure
Jul 8, 2025
Initiates: Buy
Price Target: $30
Current: $12.89
Upside: +132.74%
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.25
Upside: +1,660.00%
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $6.04
Upside: +297.35%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $22.59
Upside: +453.34%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $4.63
Upside: +288.77%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $3.09
Upside: +514.89%
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $1.89
Upside: -
Palo Alto Networks
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $202.37
Upside: -60.88%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $53.57
Upside: +189.34%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $8.80
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $9.34
Upside: +167.67%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $4.04
Upside: +44,454.46%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $30.23
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.25
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $3.26
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $1,500
Current: $5.52
Upside: +27,073.91%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $1.66
Upside: +54,116.87%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $8.55
Upside: -
Jun 6, 2017
Initiates: Buy
Price Target: $165
Current: $12.43
Upside: +1,227.43%
Apr 12, 2017
Initiates: Buy
Price Target: $225
Current: $90.50
Upside: +148.63%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $7.70
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $2.46
Upside: -